Nanotechnology-empowered combination therapy for rheumatoid arthritis: principles, strategies, and challenges

• Published in: Journal of nanobiotechnology 2024-07, Vol.22 (1), p.431-33, Article 431
• Main Authors: Ren, Shujing, Xu, Yuhang, Dong, Xingpeng, Mu, Qingxin, Chen, Xia, Yu, Yanyan, Su, Gaoxing
• Format: Article
• Language: English
• Subjects: Animals; Antirheumatic agents; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Co-delivery; Combination therapy; Combined Modality Therapy; Diagnosis; Dosage and administration; Drug Delivery Systems - methods; Drug resistance; Drug therapy; Drug therapy, Combination; Humans; Multifunctional nanomedicine; Multimodal therapy; Nanomedicine - methods; Nanoparticles - chemistry; Nanostructures - chemistry; Nanostructures - therapeutic use; Nanotechnology - methods; Nonsteroidal anti-inflammatory drugs; Patient outcomes; Prevention; Review; Rheumatoid arthritis
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-024-02670-7

Rheumatoid arthritis (RA) is an autoimmune disease with multifactorial etiology and intricate pathogenesis. In RA, repeated monotherapy is frequently associated with inadequate efficacy, drug resistance, and severe side effects. Therefore, a shift has occurred in clinical practice toward combination therapy. However, conventional combination therapy encounters several hindrances, including low selectivity to arthritic joints, short half-lives, and varying pharmacokinetics among coupled drugs. Emerging nanotechnology offers an incomparable opportunity for developing advanced combination therapy against RA. First, it allows for co-delivering multiple drugs with augmented physicochemical properties, targeted delivery capabilities, and controlled release profiles. Second, it enables therapeutic nanomaterials development, thereby expanding combination regimens to include multifunctional nanomedicines. Lastly, it facilitates the construction of all-in-one nanoplatforms assembled with multiple modalities, such as phototherapy, sonodynamic therapy, and imaging. Thus, nanotechnology offers a promising solution to the current bottleneck in both RA treatment and diagnosis. This review summarizes the rationale, advantages, and recent advances in nano-empowered combination therapy for RA. It also discusses safety considerations, drug-drug interactions, and the potential for clinical translation. Additionally, it provides design tips and an outlook on future developments in nano-empowered combination therapy. The objective of this review is to achieve a comprehensive understanding of the mechanisms underlying combination therapy for RA and unlock the maximum potential of nanotechnology, thereby facilitating the smooth transition of research findings from the laboratory to clinical practice.